Get the Stockscreener App
45.25
3.22%
1.41
Pre-market:
44.71
-0.54
-1.19%
Ptc Therapeutics Inc stock is traded at $45.25, with a volume of 774.48K.
It is up +3.22% in the last 24 hours and down -2.14% over the past month.
See More
Previous Close:
$43.84
Open:
$44.27
24h Volume:
774.48K
Relative Volume:
1.08
Market Cap:
$3.33B
Revenue:
$900.66M
Net Income/Loss:
$-453.20M
P/E Ratio:
-7.6178
EPS:
-5.94
Net Cash Flow:
$-274.19M
1W Performance:
+8.23%
1M Performance:
-2.14%
6M Performance:
+38.68%
1Y Performance:
+67.22%
1-Day Range:
$42.97
$45.28
1-Week Range:
$41.75
$45.28
52-Week Range:
$23.58
$54.16
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Name
Ptc Therapeutics Inc
Sector
Industry
Phone
(908) 222-7000
Address
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Compare PTCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
45.25 | 3.33B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-03-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Sep-04-24 | Initiated | Robert W. Baird | Outperform |
| Aug-26-24 | Resumed | UBS | Buy |
| May-20-24 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Dec-19-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Oct-30-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-27-23 | Downgrade | Citigroup | Neutral → Sell |
| Oct-06-23 | Downgrade | Truist | Buy → Hold |
| Sep-18-23 | Downgrade | Citigroup | Buy → Neutral |
| Sep-15-23 | Downgrade | Raymond James | Outperform → Underperform |
| Mar-17-23 | Initiated | SVB Securities | Market Perform |
| Dec-14-22 | Initiated | Goldman | Sell |
| Sep-12-22 | Initiated | Jefferies | Buy |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Apr-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-18-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Mar-29-21 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Feb-12-21 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-05-21 | Upgrade | Citigroup | Neutral → Buy |
| Nov-30-20 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| Oct-30-20 | Downgrade | Citigroup | Buy → Neutral |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Apr-09-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Feb-20-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-12-19 | Initiated | SunTrust | Buy |
| May-13-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Apr-11-19 | Initiated | Bernstein | Outperform |
| Oct-03-18 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-19-18 | Initiated | Credit Suisse | Outperform |
| Jun-18-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-04-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-29-18 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-16-17 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-26-17 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Oct-09-17 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Ptc Therapeutics Inc Stock (PTCT) Latest News
PTC Therapeutics Stock Soars on Novartis Licensing Agreement - MSN
Assenagon Asset Management S.A. Sells 52,794 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Gastroparesis Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and FDA Approvals | CinDome Pharma, Inc., Evoke Pharma, Vanda Pharma, Ironwood Pharma, Takeda, Neurogastrx, Inc, PTC Thera - The Globe and Mail
William Blair Boosts Earnings Estimates for PTC Therapeutics - MarketBeat
PTC Therapeutics' SWOT analysis: rare disease biotech stock faces pivotal year - Investing.com Australia
Cantor Fitzgerald Issues Pessimistic Forecast for PTC Therapeutics (NASDAQ:PTCT) Stock Price - MarketBeat
PTC Therapeutics sees several potential catalysts in 2025 - MSN
Orsini the Exclusive Specialty Pharmacy Provider for Gene Therapy KEBILIDI™ (eladocagene exuparvovec-tneq) - Yahoo Finance
Muscular Dystrophy Treatment Market Next Big Thing Forecast By 2031 | Santhera Pharmaceuticals, PTC Therapeutics - openPR
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
PTC Therapeutics Surpasses Revenue Guidance for 2024 - TipRanks
PTC Therapeutics reports $814 million in 2024 revenue, surpassing goals - Investing.com
PTC Therapeutics reports $814 million in 2024 revenue, surpassing goals By Investing.com - Investing.com South Africa
PTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare Conference - Longview News-Journal
Ptc Therapeutics' chief accounting officer sells $132,492 in stock - Investing.com India
Ptc Therapeutics' chief accounting officer sells $132,492 in stock By Investing.com - Investing.com South Africa
PTC Therapeutics CEO Eric Pauwels sells $167,550 in stock By Investing.com - Investing.com South Africa
Ptc Therapeutics exec VP sells shares worth $158,870 By Investing.com - Investing.com Australia
Ptc Therapeutics CEO Matthew Klein sells $204,007 in stock - Investing.com India
Ptc Therapeutics CEO Matthew Klein sells $204,007 in stock By Investing.com - Investing.com Australia
Ptc Therapeutics exec VP sells shares worth $158,870 - Investing.com India
Ptc therapeutics' EVP sells $90,036 in stock By Investing.com - Investing.com Australia
PTC Therapeutics, Inc. (NASDAQ:PTCT) EVP Lee Scott Golden Sells 810 Shares - MarketBeat
Insider Selling: PTC Therapeutics, Inc. (NASDAQ:PTCT) VP Sells 1,543 Shares of Stock - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) CAO Christine Marie Utter Sells 1,291 Shares - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Insider Neil Gregory Almstead Sells 1,265 Shares - MarketBeat
Ptc therapeutics’ EVP sells $90,036 in stock By Investing.com - Investing.com Nigeria
PTC Therapeutics CEO Eric Pauwels sells $167,550 in stock - Investing.com
Ptc Therapeutics executive Neil Almstead sells shares worth $133,674 - Investing.com
Ptc therapeutics' EVP sells $90,036 in stock - Investing.com
JPMorgan Chase & Co. Cuts Stock Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Denali Suffers Another ALS Fail With Phase II/III Flop - BioSpace
Have Insiders Sold PTC Therapeutics Shares Recently? - Simply Wall St
Where are the Opportunities in (PTCT) - Stock Traders Daily
Ptc Therapeutics CEO Matthew Klein sells $373,879 in stock By Investing.com - Investing.com Australia
Ptc Therapeutics CEO Matthew Klein sells $373,879 in stock - Investing.com India
PTC Therapeutics, Inc. (NASDAQ:PTCT) CEO Matthew B. Klein Sells 8,279 Shares - MarketBeat
PTC Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation - Quantisnow
Brokerages Set PTC Therapeutics, Inc. (NASDAQ:PTCT) Price Target at $54.08 - MarketBeat
Long Term Trading Analysis for (PTCT) - Stock Traders Daily
PTC Therapeutics Stock Eyes Further Rally After Price-Target Hikes On Huntington’s Therapy Deal With Novartis: Retail Buzz Grows - MSN
Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion - MSN
PTC Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Geode Capital Management LLC Acquires 10,886 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC upgraded to outperform by RBC on Novartis deal - MSN
PTC Therapeutics ALS drug fails to meet endpoints as trials shut down - MSN
Ptc Therapeutics Inc Stock (PTCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):